Friday, 25th January, 2013, 12.00
Speaker: Fernando Danilo González Nilo, Center for Bioinformatics and Integrative Biology (CBIB), Santiago de Chile, Chile.
Room Marie Curie
Friday, 7th December, 2012, 12:00 - 13:00
Speaker: Josh Stuart, Systems Biology Group-University of California, Santa Cruz, USA
Room Marie Curie Room
Thursday, 29th November, 2012, 11:00
Speaker: Cinta Pegueroles - Biomedical Informatics - GRIB (IMIM/ UPF)
Room Aula (473.10)
Wednesday, 26th September, 2012
Drug Design 2012, Oxford, UK, 26-28 September, 2012
Speaker: Gianni de Fabritiis
Tuesday, 18th September, 2012
VPH 2012 Conference, London, UK, 18-20 September 2012
Speaker: Obiol-Pardo C, Gomis-Tena J, Sanz F, Saiz J, Pastor M
Sunday, 2nd September, 2012
International Symposium on Medicinal Chemistry, Berlin, Germany. 2-6 September 2012
Speaker: Carrió P, Cases M, Sanz F, Pastor M
Friday, 13th July, 2012, 11:00-12:00
Alzheimer’s disease (AD) is a disruptive brain disorder characterized by a massive neuronal loss leading
to a progressive decline of cognitive function. The cause of AD is poorly understood. Several hypotheses have been proposed over the years to explain the disease and to identify relevant drug targets. It has been shown that AD is always associated with the formation of plaques (amyloid hypothesis) as well as with the deposition of neurofibrillary tangles (tau hypothesis).
There are few currently approved drugs, and these offer just a small benefit for a relatively short period of time. Nowadays, AD represents the largest unmet medical need in neurology.
Our approach to drug discovery in AD has been based on a radical change of the classical ‘one-drug one-target’ paradigm into a multitarget drug discovery approach. In this seminar, two different series of molecules discovered following the multitarget strategy will be presented. The initial steps of our drug discovery strategy will be discussed, from structure-based drug design, carried out by means of computational tools, to chemical syntheses, and in vitro and in vivo characterization.
Speaker: Dr. Andrea Cavalli, Italian Institute of Technology (IIT), Genova, Italy
Room Xipre (seminar 173.06-183.01)
Tuesday, 5th June, 2012
2nd Aegean Conference on Molecular Recognition, Rodos Palace Conference Center, Ixia, Rhodes, Greece, 5-10 June 2012.
Speaker: Gianni de Fabritiis
Friday, 1st June, 2012, 11:00-12:00
The use of weak binding “fragments” of molecules is now recognised as an efficient and robust method of hit identification in the drug discovery process. The use and integration of fragment hits into successful lead optimisation is the critical determinant of whether this technology will become accepted as a significant tool in drug discovery. A number of compounds which have evolved using fragment based hit identification are now in phase I-III clinical trials suggesting that this is a technology which will find a permanent place in the armory of the Drug Discovery Scientist. At the newly established Drug Discovery Programme at the Beatson Institute for Cancer Research we are exploiting the basic biology strengths within the Beatson Institute and wider Cancer Research UK network, to investigate some of the most exciting and challenging cancer targets. Central to our strategy is Fragment-Based Drug Discovery methods and we will use NMR and Surface Plasmon Resonance as primary tools for fragment-based hit identification. I will discuss some results around our initial forays into some of these areas.
Speaker: Dr. Martin Drysdale, Drug Discovery Programme, Beatson Institute for Cancer Research, Glasgow, UK
Room Charles Darwin seminar
Wednesday, 30th May, 2012
IMI Stakeholder Forum 2012, Brussels, Belgium, 30 May 2012
Speaker: Sanz F